Randomised clinical trial: Relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - A double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 6, 2014, Pages 595-602

  Thomas, E ^a   Wade, A ^b   Crawford, G ^b   Jenner, B ^a   Levinson, N ^a   Wilkinson, J ^a  

^a RECKITT BENCKISER   (United Kingdom)

^b CPS Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAVISCON; GAVISCON DOUBLE ACTION; PLACEBO; UNCLASSIFIED DRUG;

ADULT; BEDTIME DOSAGE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE TRACT PARAMETERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX DISEASE QUESTIONNAIRE SYMPTOM SCORE; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY;

ADULT; ALGINATES; ALUMINUM HYDROXIDE; ANTACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SILICIC ACID; SODIUM BICARBONATE; TREATMENT OUTCOME;

EID: 84894516097     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12640     Document Type: Review

References (40)

1. Dent J, El-Serag HB, Wallander MA, et al,. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
2. Liker H, Hungin P, Wiklund I,. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract 2005; 18: 393-400.
3. Wiklund I, Carlsson J, Vakil N,. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101: 18-28.
4. Wahlqvist P, Karlsson M, Johnson D, et al,. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008; 27: 960-70.
5. Friedenberg FK, Hanlon A, Vanar V, et al,. Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. Dig Dis Sci 2010; 55: 1911-7.
6. Shaheen NJ, Hansen RA, Morgan DR, et al,. The burden of gastrointestinal and liver diseases, 2006. J Gastroenterol 2006; 101: 2128-38.
7. Gisbert JP, Cooper A, Karagiannis D, et al,. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes 2009; 7: 90.
8. Vakil N, van Zanten SV, Kahrilas P, et al,. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
9. Portale G, Peters J, Hsieh CC, et al,. When are reflux episodes symptomatic? Dis Esophagus 2007; 20: 47-52.
10. Guillemot F, Ducrotté P, Bueno L,. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 2005; 29: 243-6.
11. Neumann H, Monkemuller K, Kandulski A, et al,. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett's esophagus. Dig Dis 2008; 26: 243-7.
12. Tack J, Caenepeel P, Arts J, et al,. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54: 1370-6.
13. Choung RS, Locke GR, Schleck CD, et al,. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil 2012; 24: 229-34, e106.
14. Fletcher J, Wirz A, Young J, et al,. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-83.
15. Kahrilas P, McColl K, Fox M, et al,. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058-64.
16. Clarke AT, Wirz AA, Seenan JP, et al,. Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic. Gut 2009; 58: 904-9.
17. Clarke AT, Wirz AA, Manning JJ, et al,. Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket. Gut 2008; 57: 292-7.
18. Beaumont H, Bennink RJ, de Jong J, et al,. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441-51.
19. Pandolfino JE, Zhang Q, Ghosh SK, et al,. Acidity surrounding the squamocolumnar junction in GERD patients: "acid pocket" versus "acid film". Am J Gastroenterol 2007; 102: 2633-41.
20. Sifrim D, Penagini R,. "Capping" the gastric acid pocket to reduce postprandial acid gastroesophageal reflux. Clin Gastroenterol Hepatol 2013; 11: 1592-4. pii: S1542-3565(13)00867-7.
21. Rohof W, Bennink R, Smout A, et al,. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11: 1585-91.
22. Hampson FC, Farndale A, Strugala V, et al,. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137-47.
23. Hampson FC, Jolliffe IG, Bakhtyari A, et al,. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm 2010; 36: 614-23.
24. Mandel KG, Daggy BP, Brodie DA, et al,. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669-90.
25. Sweis R, Kaufman E, Anggiansah A, et al,. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther 2013; 37: 1093-102.
26. Zentilin P, Dulbecco P, Savarino E, et al,. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther 2005; 21: 29-34.
27. Bredenoord AJ, Weusten BL, Curvers WL, et al,. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313-8.
28. Kwiatek MA, Roman S, Fareeduddin A, et al,. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59-66.
29. Rohof WO, Bennink RJ, de Ruigh AA, et al,. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012; 61: 1670-7.
30. Rohof W, Bennink R, Boeckxstaens G,. Effect of PPIs on the Size, Position and Acidity of the Postprandial Acid Pocket. Gastroenterology 2012; 142: S-92.
31. Shaw MJ, Talley NJ, Beebe TJ, et al,. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7.
32. Juniper EF, Guyatt GH, Willan A, et al,. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-7.
33. Jaeschke R, Singer J, Guyatt GH,. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
34. Chatfield S,. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin 1999; 15: 152-9.
35. The Scottish Government. Statistics. Health of Scotland's population-Healthy weight. Available at: http://www.scotland.gov.uk/Topics/ Statistics/Browse/Health/TrendObesity. Accessed December 5, 2013.
36. Pilichiewicz AN, Horowitz M, Holtmann GJ, et al,. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2009; 7: 317-22.
37. Reckitt Benckiser. Gaviscon Double Action Summary of Product Characteristics. Last revised 28/01/2011.
38. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for the Industry: Patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
39. Lopez-Alvarenga JC, Sobrino-Cossio S, et al,. Physicians and patients measure different dimension on assessment for gastroesophageal reflux disease-related symptoms [corrected]. J Neurogastroenterol Motil 2011; 17: 381-6.
40. Dent J, Vakil N, Jones R, et al,. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010; 59: 714-21.